This Phase I/II Trial Assesses Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphomas (PMBCL/CNS-BCL). It Explores Safety, Efficacy, and Simplifying Cell Production, Enrolling Patients From Multiple Centers

Conditions: Acute Lymphoblastic Leukemia, Adult B-Cell; Acute Lymphoblastic Leukemia, in Relapse; Non-Hodgkin Lymphoma, B-cell; Diffuse Large B Cell Lymphoma; Central Nervous System Lymphoma; Lymphoma, Follicular; MCL Interventions: Biological: CD19/CD22-CAR T cells Sponsors: Essen Biotech Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials